Cipla Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: CIPLA Large Cap ISIN: INE059A01026
As on 22 December 2024 at 23:32 IST
As on 22 December 2024 at 23:32 IST
1,506.55
+ 34.15
(2.32%)
Over 1 Month
0.45%
Over 6 Months
-4.71%
Over 1 Year
19.08%
Over 3 Years
64.70%

Cipla Ltd Summary

Close 1,506.55
Open 1,450
High 1,510.05
Low 1,449.90
Volume 34,26,222
Net Turnover (in ₹) 3,26,32,89,955.50
52 Week High 1,702.05
52 Week Low 1,205.85
52Wk High / Low
1,205.85
1,702.05

Cipla Ltd Key Financial Data

Market Cap (in ₹ Cr) 1,18,884.82
EPS (TTM) 52.42
Book Value (BV) 360.74
Div. Yield 0.88
P/E (TTM) 27.11
Price/Book Value 4.08
Delivery % 63.05
Face Value 2

Cipla Ltd Key Ratios

P/E ratio 29.60
P/B ratio 4.31
EV to Sales 7.26
PEG Ratio 0.48
ROA 14.47
ROE 15.50
Debt-Equity -
Net Profit Margin 24.60
Operating Profit Margin 35.71

Cipla Ltd Peer Comparison

Company LTP Market Cap (in ₹ Cr)
Cipla Ltd ₹1,472.45 ₹1,18,917.13
Sun Pharmaceuticals Industries Ltd ₹1,808.50 ₹4,33,919.73
Divis Laboratories Ltd ₹5,844.75 ₹1,55,159.75
Torrent Pharmaceuticals Ltd ₹3,434.25 ₹1,16,225.41
Mankind Pharma Ltd ₹2,803.45 ₹1,12,323.63
Dr Reddys Laboratories Ltd ₹1,342.45 ₹1,12,015.49

Cipla Ltd News

Cipla Ltd spurts 1.46%, up for five straight sessions

Cipla Ltd is quoting at Rs 1493.85, up 1.46% on the day as on 12:44 IST on the NSE. The stock is up 20.84% in last one year as compared to a 13.3% gain in NIFTY and a 40.24% gain in the Nifty Pharma.

19 Dec 2024

Stocks to watch: Cipla, Greaves Cotton, PC Jeweller, Shriram Finance

12 Dec 2024

Cipla Ltd down for fifth straight session

Cipla Ltd is quoting at Rs 1456.05, down 0.88% on the day as on 13:19 IST on the NSE. The stock jumped 21.11% in last one year as compared to a 16.84% rally in NIFTY and a 38.38% spurt in the Nifty Pharma index.

10 Dec 2024

Cipla Ltd drops for fifth straight session

Cipla Ltd is quoting at Rs 1478.6, down 1.41% on the day as on 13:19 IST on the NSE. The stock jumped 18.56% in last one year as compared to a 19.08% rally in NIFTY and a 37.04% spurt in the Nifty Pharma index.

18 Nov 2024

Cipla allots 17,064 equity shares under ESOS

15 Nov 2024

Cipla Ltd Financials

Profit and Loss

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Total Revenue17,64514,802.1316,047.5211,532.9913,552
Total Expenses12,698.0311,610.6312,243.148,748.9910,587.69
Profit Before Tax4,946.973,005.603,804.382,7842,964.31
Profit After Tax3,714.192,144.062,882.582,044.652,318.17
Operating Profit after Depreciation4,967.223,213.773,831.312,829.073,000.36

Balance Sheet

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Fixed Assets3,692.513,8103,927.994,022.734,088.54
Total Non Current Assets16,195.3914,225.3414,114.0112,771.5611,378.60
Total Current Assets14,857.8413,371.1311,335.0410,192.189,027.06
TOTAL ASSETS31,053.2327,596.4725,449.0522,963.7420,405.66
Total Shareholder's Fund27,973.9224,638.0922,513.5519,927.5617,402.96

Cash Flow

Particulars (in ₹ Cr.) FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Net Cash from Operating Activities3,726.773,035.052,773.433,460.312,018.14
Net Cash used in Investing Activities-2,882.90-2,758.09-2,464.14-3,361.33-1,127.18
Net Cash used in Financing Activities-708.83-424.77-426.72-65.80-693.89

Cipla Ltd Corporate Actions

Cipla Ltd

₹13/Share

Announcement Date 02 Aug 2024
Record Date 02 Aug 2024
Div Yield 650%

About Cipla Ltd

Cipla Ltd is an Indian multinational pharmaceutical company. It focuses on developing medications to treat diseases and various other medical conditions. The company operates in the pharmaceutical sector, providing a wide range of drugs, vaccines, and diagnostics. They even make contact lenses, animal health products, dietary supplements, and protein supplements.

Founded in 1935 by Khwaja Abdul Hamied as the Chemical, Industrial & Pharmaceutical Laboratories. The company’s headquarters are located in Mumbai, Maharashtra, India. The promoters of Cipla include the Hamied family, with Yusuf Hamied serving as the Chairperson and Umang Vohra as the CEO.

Cipla’s main products include medications for diseases, HIV/AIDS, oncology, and other therapeutic areas. The company is known for its innovation in developing affordable medications. For instance, they make antiretroviral drugs during the AIDS epidemic to make them more accessible.
Even though Cipla is a significant player in the pharmaceutical industry. It is not the largest in terms of market share or market capitalization in India. However, it is the third-largest drug producer in India.

The promoter shareholding in Cipla is a crucial aspect of its corporate structure. The Hamied family holds a substantial stake in the company. Here is a list of their top promoters -
  • Y K Hamied
  • M K Hamied
  • Umang Vohra
  • Samina Hamied
  • S Radhakrishnan

The registered office of Cipla is located at Cipla House, Peninsula Business Park, in Mumbai, Maharashtra, India. The company’s registrars and transfer agents are KFin Technologies Private Limited. They are situated in Selenium Tower B, Plot No. 31-32, Gachibowli in Hyderabad.

Cipla’s management team is led by Chairperson Yusuf Hamied and CEO Umang Vohra. They have been instrumental in steering the company towards growth and innovation. The company’s commitment to providing affordable healthcare solutions has made it a trusted name in the industry.

Vision and Mission

Cipla Ltd is a leading pharmaceutical company. Hence, it has a clear and compelling vision and mission that guide its operations and strategic decisions. These statements reflect the company’s commitment to better healthcare and making a positive impact on society.

Cipla’s vision is to be a leading global pharmaceutical company through its innovation and technology. They aim to provide high-quality, affordable healthcare solutions. The company aims to address the needs of patients around the world. In addition, to developing and delivering a wide range of pharmaceutical products. They envision a world where everyone can get essential medications, regardless of their situation. This vision drives the company’s efforts to expand its global footprint and enhance its product portfolio.

The vision statement emphasizes Cipla’s dedication to innovation. The company invests heavily in research and development to create better medications. It invests heavily towards cutting-edge technology and scientific advancements. They strive to stay at the forefront of the pharmaceutical industry. This focus on innovation ensures that the company can give effective treatments for various ailments.

Cipla’s mission is to provide access to high-quality and affordable medicines. This is to ensure that no patient is denied treatment due to financial constraints. The company’s mission statement underscores its commitment to social responsibility. Along with the role it can play in improving public health.

Cipla aims to make a difference in the lives of patients by offering a diverse range of pharmaceutical products. Their objective is to make medicines that meet the highest standards of quality and efficacy.
One of the key aspects of Cipla’s mission is its focus on affordability. The company is known for its efforts to make essential medications accessible to people in developing countries. Cipla’s pioneering work in producing affordable drugs for HIV/AIDS patients is a testament to its mission-driven approach. Moreover, by reducing the cost of life-saving medications, Cipla has played a major role in combating global health crises.

Cipla’s vision and mission are also closely aligned with its commitment to sustainability. The company recognizes the importance of environmental stewardship. Hence, it strives to minimize its ecological footprint. Cipla implements sustainable practices across its operations, from manufacturing to distribution.
This includes reducing waste, conserving energy, and promoting the use of renewable resources. Plus, by adding sustainability into its business model, it aims to create a healthier planet for future generations.

At the heart of Cipla’s vision and mission is a patient-centric approach. The company prioritizes the needs and well-being of patients in all its endeavors. Cipla engages with healthcare professionals and patients to understand their needs and challenges. This approach enables the company to develop solutions that tackle certain medical conditions.

Cipla’s patient-centric philosophy extends beyond the development of medications. The company also focuses on raising awareness about various health issues. It even provides education and support to patients and caregivers.They also empower patients with knowledge and resources that enable better care. This is how Cipla aims to enhance the overall healthcare experience and improve health outcomes.

Cipla’s vision and mission reflect its unwavering commitment to improving global healthcare. The company’s focus on affordability and patient-centricity drives its efforts to make a meaningful impact on society. With these core values, Cipla continues its legacy of excellence and compassion in the industry.

Cipla Ltd Stock Analysis

  1. Annual revenue for Cipla Ltd increased by 19.21% to ₹17,645 crore in FY 2024 from ₹14,802.13 crore in FY 2023.
  2. Annual Net Profit for Cipla Ltd increased by 73.23% to ₹3,714.19 crore in FY 2024 from ₹2,144.06 crore in FY 2023.
  3. Promoter Shareholding in Cipla Ltd decreased by 0.01% in the most recent quarter, from 30.86% in June 2024 to 30.86% in September 2024.
  4. Cipla Ltd delivered a 1-year return of 19.08% compared to the Nifty 50, which provided a return of 11.52% as of the last trading session.
  5. Cipla Ltd share price moved remains unchanged by 0.00% from its previous close of INR ₹1,506.55. The latest Cipla Ltd share price is INR ₹1,506.55.
  6. Cipla Ltd share price today has been at a low of 1,469.05 and a high of 1,506.60. Over the past 52 weeks, the Cipla Ltd share price has seen a low of 1,205.85 and a high of 1,702.05.

FAQ’s

What is the share price of Cipla Ltd today?

Cipla Ltd share price as on 22 Dec 2024 is ₹ 1506.55

What is the Market Cap of Cipla Ltd?

The market cap of Cipla Ltd stock is ₹1,18,884.82 Cr.

What is the PE Ratio of Cipla Ltd?

The Price to Earnings (P/E) Ratio of Cipla Ltd is 29.60

What is the PB Ratio of Cipla Ltd?

The Price to Book (P/B) Ratio of Cipla Ltd is 4.31

What is the 52 week high of Cipla Ltd Share Price?

The 52 week high of Cipla Ltd share price stands at ₹1,702.05

What is the 52 week low of Cipla Ltd Share Price?

The 52 week low of Cipla Ltd share price stands at ₹1,205.85

Get started with us today and
start building your wealth journey